Chronic myeloproliferative diseases with concurrent BCR–ABL junction and JAK2V617F mutation
Authors:
- 1 November 2007
- journal article
- Published by Springer Nature in Leukemia
- Vol. 22 (5) , 1059-1062
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelBlood, 2007
- JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemiaThe Lancet Oncology, 2007
- Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosisLeukemia, 2007
- Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutationBlood, 2007
- Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemiaLeukemia, 2007
- The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disordersBlood, 2005
- Quantitative Intra-Individual Monitoring of BCR-ABL Transcript Levels in Archival Bone Marrow Trephines of Patients with Chronic Myeloid LeukemiaThe Journal of Molecular Diagnostics, 2003
- Transformation of polycythemia vera to ph‐positive chronic myelogenous leukemiaAmerican Journal of Hematology, 1990